source
- Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalRegenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027. The biotech hopes to be the second company to com…Endpoints · 3mo ago↗ source
- STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 millionCREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.STAT · 3mo ago↗ source
- STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submissionRegenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.